Optimized production and quality control of 68Ga-DOTATATE

Iranian Journal of Nuclear Medicine

Volumn 24, Issue 1, 2016, Pages 29-36

  Aghanejad, Ayuob ^a   Jalilian, Amir Reza ^a   Maus, Stephan ^b   Yousefnia, Hassan ^a   Geramifar, Parham ^a   Beiki, Davood ^c  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ga DOTATATE; Optimization; PET CT; Production; Quality control

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAAZACYCLODODECANE TETRAACETIC ACID OCTREOTATE GA 68; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG HALF LIFE; GAMMA SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; KIDNEY TUBULE ABSORPTION; NONHUMAN; PET-CT SCANNER; QUALITY CONTROL; RADIATION DETECTOR; RAT; SOLID PHASE EXTRACTION;

EID: 85000350893     PISSN: 16812824     EISSN: 20082509     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sudbrock F, Fischer T, Zimmermanns B, Guliyev M, Dietlein M, Drzezga A, Schomäcker K. Characterization of SnO2-based (68) Ge/(68) Ga generators and (68) Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy. EJNMMI Res. 2014 Dec; 4(1):36.
2. Fazaeli Y, Jalilian AR, Amini MM, Ardaneh K, Rahiminejad A, Bolourinovin F, Moradkhani S, Majdabadi A. Development of a (68) Ga-Fluorinated Porphyrin Complex as a Possible PET Imaging Agent. Nucl Med Mol Imaging. 2012 Mar; 46(1):20-6.
3. 68Ga-radiopharmaceutical development. Theranostics. 2013 Dec. 10;4(1):47-80.
4. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SW. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2003 Dec; 10(4):451-8.
5. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68) Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001 Dec; 28(12):1751-7.
6. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007 Apr; 48(4):508-18.
7. Jindal T, Kumar A, Venkitaraman B, Dutta R, Kumar R. Role of (68) Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J Intern Med. 2010 Dec; 25(4):386-91.
8. Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 2014 Feb; 55(2):204-10.
9. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014 May; 55(4):389-98.
10. Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, Kanmaz B. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013 Nov; 34(11):1084-9.
11. Herrmann K, Czernin J, Wolin EM3, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med. 2015 Jan; 56(1):70-5.
12. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005 Apr; 32(4):478-85.
13. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med. 1997 Sep-Dec; 70(5-6):471-9.
14. Gromada J, Høy M, Buschard K, Salehi A, Rorsman P. Somatostatin inhibits exocytosis in rat pancreatic alphacells by G (i2)-dependent activation of calcineurin and depriming of secretory granules. J Physiol. 2001 Sep. 1;535(Pt 2):519-32.
15. Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E. Treatment with tandem [(90) Y]DOTA-TATE and [(177) Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010 Feb; 54(1):84-91.